While the world focuses on AI and biotech startups, Mopec operates in the shadows of the $100B+ forensic and pathology industry. They don't sell software; they sell the hardware that literally holds the human body together during autopsy. It’s a capital-intensive, highly regulated, and deeply entrenched business model that is nearly impossible to disrupt from the outside.

"Mopec isn't selling products; they are selling compliance, safety, and workflow reliability in the most sensitive environments imaginable."

The company's leadership team—Wilson Dias (Manufacturing), Lee Kramer (Sales), Jeff Pemberton (Marketing)—is structured for B2B enterprise sales, not consumer growth. They aren't chasing viral loops; they are chasing GSA contracts and state-level procurement deals. The undefined top countries in their traffic data likely points to US government traffic (which often masks geo-location) or referral traffic from institutional intranets, further cementing their moat in the public sector.

• **Capital Intensity:** Unlike digital health startups, Mopec requires physical manufacturing capabilities for heavy equipment like autopsy saws and tables.
• **High Switching Costs:** Once a morgue integrates Mopec's equipment and consumables, switching vendors is operationally painful and expensive.
• **Regulatory Moat:** Selling into forensic pathology requires navigating strict FDA and government compliance standards that take years to master.